sPLA2-IIA inhibition as a therapeutic target for FTLD-GRN and neurodegenerative diseases

Overview

This research program targets sPLA2-IIA, a secreted phospholipase enzyme involved in inflammatory responses, as a novel therapeutic approach for neurodegenerative diseases. The work is based on the discovery that Progranulin (PGRN), a protein whose deficiency causes frontotemporal lobar degeneration (FTLD-GRN), naturally inhibits sPLA2-IIA to control neuroinflammation. Mutations in the GRN gene leading to PGRN haploinsufficiency are a leading cause of FTLD, while PGRN polymorphisms have been associated with Alzheimer's disease and Parkinson's disease. By developing inhibitors of sPLA2-IIA, this program aims to address the underlying neuroinflammatory mechanisms in these devastating conditions, offering a potential new pathway for treatment where current options are limited.

Technical specifications

• Target identification: sPLA2-IIA has been identified as a critical downstream target of PGRN that mediates neuroinflammatory responses
• Mechanism of action: PGRN interacts with sPLA2-IIA to downregulate both its levels and enzymatic activity; inhibiting sPLA2-IIA mimics this protective effect
• Validation evidence: Studies in PGRN-deficient mice demonstrate that sPLA2-IIA inhibition rescues both inflammation and lysosomal abnormalities associated with PGRN deficiency
• Therapeutic approaches: Planned development of both small molecule and antibody-based inhibitors of sPLA2-IIA
• Disease applications: Primary indication is FTLD-GRN, with potential expansion to Alzheimer's disease, Parkinson's disease, and other conditions involving neuroinflammation

Technology readiness level

The program is at an early-to-mid stage of preclinical development. The target has been validated through genetic and pharmacological studies in mouse models, demonstrating that sPLA2-IIA inhibition rescues key disease phenotypes including inflammation and lysosomal dysfunction. Future validation plans include developing novel small molecule and antibody-based sPLA2-IIA inhibitors and testing their efficacy in Grn-deficient mice, with potential extension to additional neuroinflammatory disease models. The research originates from Cornell University with established expertise in neurodegeneration and neuroinflammation biology.